Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Esther Tolani
Observed names:
E Tolani,
E. Esther Tolani,
E. Tolani
Institution:
King's College London
Observed institutions:
King's College London,
IQVIA (United Kingdom),
London School of Hygiene & Tropical Medicine,
IQVIA (United States),
Kings Health Partners
ORCID:
0000-0002-7415-0859
Observed ORCID:
0000-0002-7415-0859
OpenAlex ID:
A5030291784
Text mining occupations from the mental health electronic health record: a natural language processing approach using records from the Clinical Record Interactive Search (CRIS) platform in south London, UK
2021
·
Natasha Chilman
, Xingyi Song
, et al.
·
BMJ Open
·
36
PDF
Eliciting the mechanisms of action of care navigators in the management of type 2 diabetes in people with severe mental illness: A qualitative study
2022
·
Iliatha Papachristou Nadal
, Catherine Cliffton
, et al.
·
Diabetic Medicine
·
11
PDF
Recurrent cardiovascular and limb events in 294,428 patients with coronary or peripheral artery disease or ischemic stroke on antiplatelet monotherapy: The RESRISK cohort study
2024
·
Antonio J. Vallejo-Vaz
, Kanika I. Dharmayat
, et al.
·
Atherosclerosis
·
9
Mind the Gaps: Literature Survey Reveals Shortcomings in Handling Missing Data in Clinical Practice Research Datalink (CPRD), a UK Primary Care Health Records Database
2025
·
Esther Tolani
, Miriam Carpenter
, et al.
·
Clinical Epidemiology
·
7
PDF
Patient and public involvement in integrated psychosocial care
2019
·
Io Vassiliadou
, Esther Tolani
, et al.
·
Journal of Integrated Care
·
4
372P Global real-world (rw) study of patients (pts) with epidermal growth factor receptor (EGFR) mutated advanced non-small cell lung cancer (NSCLC) treated with first-line (1L) osimertinib: Interim analysis of an rw pt registry in Germany
2022
·
F. Griesinger
, S. Popat
, et al.
·
Annals of Oncology
·
3
P48.17 Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib
2021
·
J. Nieva
, A. Taylor
, et al.
·
Journal of Thoracic Oncology
·
1
Atherothrombotic residual risk in coronary and peripheral artery disease patients on guideline-recommended antiplatelet monotherapy: baseline preliminary results from the RESRISK study
2021
·
A Vallejo-Vaz
, K I Dharmayat
, et al.
·
European Heart Journal
·
1
PDF
3 Dimenions for Long Term Conditions - creating a sustainable bio-psycho-social approach to healthcare
2019
·
Lindsay Ip
, Abigail Smith
, et al.
·
International Journal of Integrated Care
·
1
A Prospective Pre–Post Evaluation of the Three Dimensions of Care (3DLC): An Integrated Mental Health and Social Care Model for Long‐Term Conditions
2026
·
Iliatha Papachristou Nadal
, A. Abigail Smith
, et al.
·
Health & Social Care in the Community
PDF
Do comorbidities and residual risk factors influence choice of antiplatelet monotherapy in patients with peripheral artery disease? Results from the cross-sectional resrisk-pad study
2023
·
A.J. Vallejo-Vaz
, K. Dharmayat
, et al.
·
Atherosclerosis
PDF
Global real-world (rw) study of patients (pts) with epidermal growth factor receptor (EGFR) mutated advanced non-small cell lung cancer (NSCLC) treated with first-line (1L) osimertinib: interim analysis of an rw pt registry in Germany
2023
·
F Griesinger
, S Popat
, et al.
·
Pneumologie
Residual risk of major adverse cardiovascular and limb events among different atherosclerotic cardiovascular disease phenotypes receiving guideline-recommended antiplatelet monotherapy: The resrisk study
2022
·
A.J. Vallejo-Vaz
, K.I. Dharmayat
, et al.
·
Atherosclerosis
PDF
Show more works
View as search
Works count:
13
Citation count:
73
H-index:
4
I10-index:
2
Year
Topic
Type